Overdiagnosis in Modern Screening Programs : The Hidden Epidemic We Rarely Talk About

Описание: Modern screening programs are often presented as one of medicine’s greatest achievements. From mammography for breast cancer to PSA testing for prostate cancer and low-dose CT scans for lung cancer, early detection has become synonymous with prevention. The logic seems straightforward: find disease earlier, treat it earlier, and save more lives. Yet the reality is more complex. As diagnostic technologies become increasingly sensitive, they are detecting abnormalities that may never have caused symptoms or harm. This phenomenon known as overdiagnosis has become one of the most important and least understood challenges in contemporary healthcare.

Overdiagnosis does not mean a test result is incorrect. Rather, it refers to the accurate identification of a real condition that would have remained harmless throughout a person’s lifetime. Many cancers, for example, vary widely in their behavior. Some are aggressive and life-threatening, while others grow so slowly that they never progress to cause clinical problems. However, once a condition is labeled as “cancer” or “disease,” it often triggers further testing, biopsies, surgery, radiation, or medication. In these cases, the harm can come not from the disease itself, but from the cascade of interventions that follow detection.

Several large screening initiatives have highlighted this concern. The widespread use of thyroid ultrasound dramatically increased thyroid cancer diagnoses in certain populations, yet mortality rates remained largely stable. Similar debates surround PSA testing for prostate cancer and routine mammography in specific age groups. In each case, researchers have questioned how many detected cases would have remained indolent if left undiscovered. When detection rates rise sharply without a proportional drop in advanced disease or mortality, overdiagnosis becomes a serious consideration.

The consequences extend beyond physical side effects. A diagnosis can carry psychological weight, creating anxiety and long-term stress even when the condition is low risk. Economically, additional imaging, specialist consultations, and treatments place strain on both individuals and healthcare systems. Statistical factors such as lead-time bias and length bias can further complicate how screening benefits are interpreted, sometimes making outcomes appear more favorable than they truly are.

None of this suggests that screening lacks value. On the contrary, targeted screening has saved countless lives when applied appropriately. The key challenge is balance ensuring that benefits clearly outweigh harms. Risk-based approaches, improved communication of absolute versus relative risk, and shared decision making between patients and clinicians are increasingly central to responsible screening practices. As medicine continues to advance, understanding overdiagnosis is essential to preserving trust in preventive care while minimizing unintended harm.